London Stock Exchange welcomes WideCells Group PLC

London Stock Exchange welcomes WideCells Group PLC

WideCells Group PLC (EPIC: WDC), the support services provider to the growing stem cell industry, was today welcomed to London Stock Exchange in celebration of its entry to the Main Market, following a successful raise of £2 million by way of a Placing organised by Shard Capital Stockbroker and Smaller Company Capital Ltd.

The Group has established three primary divisions to deliver an end-to-end service offering that provides excellence in cord blood banking, affordable ways for families to access treatment, and education and training for healthcare professionals:

  • CellPlan – a first of its kind insurance plan to make stem cell treatment accessible and affordable, providing access to renowned specialists and hospitals globally with financial cover for medical treatment, travel, and accommodation expenses
  • WideCells – providing stem cell processing and storage facilities for a wide range of human tissues. Currently have access to a facility in Sao Paulo, Brazil and developing a facility in Manchester, UK with subsidiaries in both Portugal and Spain
  • WideAcademy – the R&D, education and training branch of the Group will offer a series of online stem cell training programmes for healthcare professionals, which will help to accelerate the growth and uptake of stem cell treatments

With a world-class leadership team in place, including recently appointed director Dr Marilyn Orcharton, founder of the UK’s foremost dental healthcare plan Denplan, the Group plans to develop its unique service offering to make cutting-edge stem cell treatments more accessible and affordable to families worldwide.

Joao Andrade, CEO of WideCells Group today said:

“Today marks a major milestone in the development of WideCells Group and I am delighted that we have successfully listed on the Main Market of London Stock Exchange.

“As the first company to ever create an integrated service offering to combat the financial barriers associated with stem cell treatment, we hope to lead the way in making potentially lifesaving treatments more accessible. In turn, we believe that this could fuel further investment into stem cell research, which has the potential to drive forward one of the next important phases in the medical industry.

“With our unique proposition and having secured an excellent management team, we are looking forward to the coming period as we continue to build WideCells Group into a recognisable name in the stem cell services industry.”

Shard Capital Stockbrokers and Smaller Company Capital are acting as the Company’s brokers. Its solicitors are Fladgate LLP and its financial PR advisers are St Brides Partners Ltd.